Brand Index Methodology
The Morning Consult Brand Index is an indicator of brand strength among consumers. Each Fortune 500 company receives a score based on a ratio of favorable to unfavorable impressions among U.S. adults and its overall favorability. This ensures that a score takes into account how well-liked a company is among people who have an opinion of it without penalizing companies that are not consumer-facing.
Morning Consult polls thousands of adults across the country each week. The surveys are conducted online using large, established online survey vendors. The data is weighted to approximate a nationally representative sample based on age, race/ethnicity, gender, educational attainment, region, annual household income, home ownership status and marital status.
In Ian Read’s final year as the company’s CEO, Pfizer managed to grow revenues by just 2% as it adjusted to greater competition to—and diminished sales of—Viagra and other drugs on which the company lost patent exclusivity in 2017. The pharmaceutical giant is now in the midst of a reorganization since announcing in the summer of 2018 that it would separate its business into three parts, one of which (its consumer health division) it plans to merge into a joint venture with GlaxoSmithKline. The moves are designed to position Pfizer for greater sales growth under new CEO Albert Bourla.
CEO
Albert Bourla
CEO Title
Chief Executive Officer & Director
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
New York, N.Y.
Website
Years on Fortune 500 List
65
Employees
92,400
SPONSOR CENTER
| $ millions | % change | |
|---|---|---|
| Revenues ($M) | $53,647 | 2.1% |
| Profits ($M) | $11,153.0 | -47.7% |
| Assets ($M) | $159,422 | |
| Total Stockholder Equity ($M) | $63,407 |
| Profit as % of Revenues | 20.8% | |
| Profits as % of Assets | 7.0% | |
| Profits as % of Stockholder Equity | 17.6% |
| Earnings Per Share ($) | 1.87 | |
| EPS % Change (from 2017) | -46.9% | |
| EPS % Change (5 year annual rate) | -10.1% | |
| EPS % Change (10 year annual rate) | 4.5% |
| Total Return to Investors (2018) | 24.7% | |
| Total Return to Investors (5 year, annualized) | 11.2% | |
| Total Return to Investors (10 year, annualized) | 13.8% |
- Previous Close:
- Market Cap: NaNB
- Next Earnings Date:
- High:
- Low:
- 52 Week High:
- 52 Week Low:
- 52 Week Change %: 0.00
- P/E Ratio: n/a
- EPS:
- Dividend Yield: n/a
News about Pfizer
Walmart’s new robot “smart assistants” are good news for employees.
This is your Data Sheet newsletter for Thursday, April 4, 2019.
Must-read business news, delivered every morning.
Pfizer also makes and markets a generic formula of its popular patented pill.
Prevnar 13 protects against infections including pneumonia, and is more popular than ever, thanks to the CDC.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc.. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html. S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions